Navigation Links
TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Date:10/20/2008

LA JOLLA, Calif., Oct. 20 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced it initiated dosing of the first cohort of subjects in a Phase I multiple dose clinical trial of NGX426, the oral prodrug of its most advanced product candidate, tezampanel. The trial is designed to evaluate the safety, tolerability and pharmacokinetics of NGX426 when given once daily for five consecutive days. NGX426 has been safely administered to more than 150 healthy adults in single doses from 10 to 210 mg. Data from the multiple dose trial will support the development of NGX426 in chronic pain indications such as neuropathic pain.

The double-blind, placebo-controlled, Phase I multiple dose trial is being conducted at a single center in the United States. A total of 20 healthy male and female adult volunteers will be enrolled in two sequential dose-escalating cohorts and will receive once daily oral doses of placebo, 90 mg or 150 mg of NGX426 for five consecutive days. These same dose strengths of NGX426 are currently being evaluated by TorreyPines in a Phase I single dose capsaicin induced hyperalgesia trial to evaluate the analgesic effect of NGX426. Results from this single dose trial are expected to be announced in December 2008.

"We are pleased with our development progress for NGX426. This novel, oral, non-opioid product candidate could potentially address significant unmet needs in treating migraine and other forms of chronic pain such as neuropathic pain," said Ev Graham, acting chief executive officer of TorreyPines Therapeutics. "The multiple dose trial, as well as the ongoing Phase I capsaicin trial evaluating the analgesic effect of NGX426, will guide us in planning our Phase II program."

Tezampanel
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
2. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
3. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
4. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
5. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
6. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
7. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. TorreyPines Therapeutics Reports Third Quarter 2007 Results
10. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... New York, NY (PRWEB) May 21, 2013 ... years. And according to My Cleaning Products, many turn to ... However, because of the health and environmental risks those solutions ... bugs with Bed Bug Bully instead. , According ... on bed bugs as they used to be. It shared ...
(Date:5/21/2013)... NANONEX CORPORATION, a pioneer and leading company ... successful delivery and installation of a new nanoimprint ... major Japanese manufacturing company. , ... lithography tool that has the ability to process ... types. Based on Nanonex inventions and proprietary technologies, ...
(Date:5/21/2013)... Vital Imaging ™ has teamed ... San Diego for a joint study which aims to ... Resonance Imaging) with that of a supine Dynawell MRI ... of improved healthcare by combining cutting edge technology with ... valuable tool for evaluating pathological changes in the spine, ...
(Date:5/21/2013)... 21, 2013 SoundConnect is pleased to ... Lync, for customers in Canada. Lync is the ... will allow businesses and organizations to collaborate and communicate ... released Lync in the United States. With the progressive ... product release in Canada, SoundConnect now offers a complete ...
Breaking Biology Technology:New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3
... SHANGHAI, Sep. 4 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: ... Chinese firm,specializing in the manufacture, research, development, marketing ... Company,s,management team will attend the Susquehanna International Group ... The SIG 3rd Annual ...
... , AURORA, Ontario, Sept. 4 Helix BioPharma ... has accepted subscriptions for the purchase, by way of private placement, ... gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private ... unit consists of one common share and one common share purchase ...
... Kendle (Nasdaq: KNDL ), a leading, global full-service ... the upcoming Robert Baird 2009 Health Care Conference on Sept. ... New York City. , , (Logo: ... Kendle,s formal presentation will be given by Senior Vice President ...
Cached Biology Technology:China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit 2Helix BioPharma Announces $13.5 Million Private Placement 2Kendle to Present at Robert Baird 2009 Health Care Conference 2
(Date:5/21/2013)... cells in the blood often jump into action ... that can fight off illness. But repeated infections ... leading to the development of serious blood conditions ... led by biologists at the California Institute of ... the molecule microRNA-146a (miR-146a) acts as a critical ...
(Date:5/21/2013)... Water Center today awarded 12 research grants, totaling ... protection efforts. , The two-year grants of up ... to track the remediation of harmful algae blooms; ... weedy plant invasions; study chromosomal damage in tree ... activities. , The grants were awarded to multidisciplinary ...
(Date:5/21/2013)... Society (ACS), the world,s largest scientific society, invites ... & Exposition, September 8-12, 2013, in Indianapolis, Ind. ... Center and at area hotels. , With more ... science,s horizons from astronomy to zoology ― ... journalists a rich assortment of spot news and ...
Breaking Biology News(10 mins):Keeping stem cells strong 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
... life has come from the fossil record, but how accurately does ... Earth? "It,s a question that goes back a long way ... and tried to understand what it tells us about the history ... Wisconsin-Madison. In fact, the fossil record can tell us a ...
... (UV) radiation of sunlight can result in skin damage and ... mutations in the DNA, which can interfere with or even ... cell function. The Dewar lesion is one of the ... the mechanism that leads to the formation of the Dewar ...
... ( Panthera uncia ) lives high in the mountains across ... numbers of this beautiful large cat are largely unknown. It ... 500 distributed across Nepal,s northern frontier. New research published in ... has used genetic analysis to show that the numbers of ...
Cached Biology News:Ancient environment led to Earth's current marine biodiversity 2When inflexibility is counterproductive: Mechanism of UV-induced DNA Dewar lesion revealed 2When inflexibility is counterproductive: Mechanism of UV-induced DNA Dewar lesion revealed 3Counting cats: The endangered snow leopards of the Himalayas 2
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
... 1 g. High quality kits ... preparation that give consistent and ... and tissues.Clean up samples from ... Accurately quantitate protein for first-dimension ...
... 50 Microplate Reader accessory for ... analysis by extending the versatility ... Cary 50 instruments. Use it ... samples in microlitre volumes, at ...
GOAT ANTI CARICA PAPAYA PAPAIN...
Biology Products: